

17 March 2026

ASX Announcement

Firebrick appoints Head of Business Development to drive market expansion

- Seasoned pharmaceutical licensing executive appointed as Head of Business Development and Licensing for Firebrick Pharma
- Goal of the new role is to drive the number of markets where Nasodine is approved and/or sold from 3 countries to up to 10 countries over 3 years

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that following an independent international search, the Company has appointed Nilesh Wadhwa as Head of Business Development and Licensing for the Company.

Nilesh joins the Company with around 30 years of high-level experience in pharmaceutical partnering, international strategy, and market expansion throughout a notable career within some of the world's leading healthcare organizations. He has led external innovation partnering and executed major transactions and new ventures across Asia for Johnson & Johnson, managed regional business development and strategy across the Asia-Pacific for Sanofi and Takeda Pharmaceuticals, and spearheaded international business growth and strategic initiatives for Alembic Pharmaceuticals.

He has extensive experience in the partnering of pharmaceuticals, medical devices, and consumer health products, having successfully negotiated and executed dozens of complex cross-border transactions across Asia-Pacific, the US, and Europe.

"Nilesh joins us at a pivotal time in Firebrick's development, as we seek to drive Nasodine approvals and licensing agreements in new markets across Asia-Pacific and elsewhere," said Dr Peter Molloy, Executive Chairman, Firebrick Pharma. "Our stated goal is to go from two products in just three countries to four products in up to 10 countries over the next three years; Nilesh will be key to achieving that goal."

Incoming Head of Business Development and Licensing, Nilesh Wadhwa commented: "I am thrilled to join Firebrick Pharma at such a crucial stage in its journey. The Company's innovative portfolio and clear vision for international expansion present a unique opportunity, and I look forward to working with Peter and the team to drive commercial success and long-term value for our shareholders."

The new role is effective from 1 April 2026 and will be based in Australia following a transition period over the next few months.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and plans to expand sales to up to 10 markets over three years. For further information, visit: firebrickpharma.com

Contacts:**Media contact:**

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com